KDR and head and neck squamous cell carcinoma: A single-center phase I/II study investigated the combination of the vascular endothelial growth factor receptor (VEGFR) inhibitor ramucirumab plus P in 40 R/M HNSCC patients, including 4 (11%) with LSCC.